Syntax Advisors’s Gilead Sciences GILD Stock Holding History

Syntax Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$229K	Buy	3,050 +108	+4%	+$8.31K	0.2%	141
2023 Q2	$227K	Sell	2,942 -69	-2%	-$5.5K	0.18%	169
2023 Q1	$250K	Buy	3,011 +265	+10%	+$21.9K	0.19%	154
2022 Q4	$236K	Sell	2,746 -1,193	-30%	-$94.5K	0.2%	146
2022 Q3	$243K	Sell	3,939 -22	-0.6%	-$1.39K	0.21%	127
2022 Q2	$245K	Buy	3,961 +4	+0.1%	+$248	0.21%	133
2022 Q1	$235K	Buy	3,957 +259	+7%	+$16.6K	0.2%	167
2021 Q4	$269K	Buy	+3,698	New	+$255K	0.2%	153

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Syntax Advisors's GILD Position: Q3 2023 in Review

Syntax Advisors increased its Gilead Sciences (GILD) stake by 3.7% in Q3 2023, buying an estimated $8.31K and bringing the position to 3,050 shares worth $229K. The position accounts for 0.2% of the portfolio, ranked #141.

Syntax Advisors first reported a position in GILD in Q4 2021 and has held it in 8 quarters since. The position peaked at $269K in Q4 2021. 1,681 funds tracked by Wall St. Rank hold GILD as of Q3 2023.

Syntax Advisors held 3,050 shares of Gilead Sciences worth $229K as of Q3 2023.
Syntax Advisors bought 108 Gilead Sciences shares in Q3 2023, an estimated $8.31K.
Gilead Sciences made up 0.2% of Syntax Advisors's portfolio in Q3 2023, its #141 holding.
Syntax Advisors first reported a position in Gilead Sciences in Q4 2021 and has held it in 8 quarters since.
Syntax Advisors's Gilead Sciences position peaked at $269K in Q4 2021.
1,681 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2023.

Based on Syntax Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.